1. Intravenous Recombinant Tissue-Type Plasminogen Activator Thrombolysis for Acute Central Retinal Artery Occlusion
- Author
-
Yan Suo, Xiaotang Wang, Yanchun Zhang, Runjia Lei, Meixia Ren, Yong Liu, Dan Qin, and Ying Wang
- Subjects
Visual acuity ,Retinal Artery Occlusion ,medicine.medical_treatment ,Cochrane Library ,03 medical and health sciences ,0302 clinical medicine ,Fibrinolytic Agents ,medicine ,Humans ,Thrombolytic Therapy ,030223 otorhinolaryngology ,Adverse effect ,Stroke ,business.industry ,030206 dentistry ,General Medicine ,Thrombolysis ,medicine.disease ,Clinical trial ,Otorhinolaryngology ,Tissue Plasminogen Activator ,Anesthesia ,Central retinal artery occlusion ,Surgery ,medicine.symptom ,Complication ,business - Abstract
Introduction Central retinal artery occlusion (CRAO), an ocular stroke, causes severe and permanent visual impairment. Thrombolytic therapy is currently the main treatment option for CRAO. Intravenous thrombolysis with recombinant tissue-type plasminogen activator (rt-PA) has been extensively applied in the treatment of CRAO with the proven advantages of effectiveness and safety. This meta-analysis aimed to assess the efficacy of intravenous rt-PA thrombolysis for the management of CRAO by evaluating the pooled evidence. Methods A comprehensive literature search of electronic databases including PubMed, OVID, and Cochrane Library was conducted up to and including March 2019. All studies reporting visual outcomes after CRAO with thrombolytic therapy were collected. Data on visual acuity and adverse events were recorded and assessed in this analysis. Data were inputted into the statistical software of STATA. The studies were weighed by the inverse of the variance and merged in a random-effects model. Results The systematic review process yielded 7 eligible studies including 121 patients with CRAO who received the intravenous rt-PA treatment. Sixty-two patients showed improvement in visual acuity (52.0%; 95% CI, 34.0%-70.0%) following rt-PA intravenous thrombolytic therapy. The observed improvement rate in the intravenous rt-PA treatment group was significantly higher than the conservative treatment group (40.4% vs. 13.0%; OR = 5.16; 95% CI, 1.90-14.05). The incidence rate of complications was relatively low (11 out of the 121 patients). Hemorrhage (9/11) was the major reported complication. Mortality was zero. Discussion This meta-analysis indicated that intravenous rt-PA thrombolysis could be an effective and safe strategy for the management of CRAO. However, a more detailed large-scale clinical trial is warranted to strengthen the evidence-based therapeutic guidance.
- Published
- 2020